Farther Finance Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Farther Finance Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$812	Sell	54 -795	-94%	-$19.1K	﹤0.01%	5642
2026 Q2	$28.1K	Buy	849 +287	+51%	+$7.13K	﹤0.01%	3709
2026 Q1	$12K	Buy	562 +425	+310%	+$9.57K	﹤0.01%	3982
2025 Q4	$3.15K	Buy	137 +114	+496%	+$3.75K	﹤0.01%	4513
2025 Q3	$692	Buy	23 +4	+21%	+$120	﹤0.01%	4459
2025 Q2	$691	Hold	19	–	–	﹤0.01%	3979
2025 Q1	$643	Buy	+19	New	+$790	﹤0.01%	3730
2024 Q1	–	Sell	-1	Closed	-$48	–	3712
2023 Q4	$48	Buy	+1	New	+$39	﹤0.01%	3386

Other funds holding RARE

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's RARE Position: Q3 2026 in Review

Farther Finance Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 94% in Q3 2026, selling an estimated $19.1K and leaving 54 shares worth $812. The position accounts for ﹤0.01% of the portfolio, ranked #5642.

Farther Finance Advisors first reported a position in RARE in Q4 2023 and has held it in 8 quarters since. The position peaked at $28.1K in Q2 2026. 4 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

Farther Finance Advisors held 54 shares of Ultragenyx Pharmaceutical worth $812 as of Q3 2026.
Farther Finance Advisors sold 795 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $19.1K.
Ultragenyx Pharmaceutical made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5642 holding.
Farther Finance Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and has held it in 8 quarters since.
Farther Finance Advisors's Ultragenyx Pharmaceutical position peaked at $28.1K in Q2 2026.
4 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.